Company news: Novo; J&J's McNeil; BMS

Share this article:
The FDA told Novo Nordisk it's going to have to cool its heels a little longer for a decision on its long-acting insulin degludec/aspart. An advisory panel was set to review the drug in June, then pushed it off until October, and the FDA just told told Novo the drug review has been shuffled a third time: a panel is set to give the drug a once-over in November. Novo's website says degludec/aspart helps maintain glucose levels over sustained periods of time, keeping them constant for between eight and 40 hours.

Johnson & Johnson is slashing 200 jobs at a Tylenol plant in Puerto Rico, reported the Associated Press. The news outlet said it cuts are part of a modernization push --- the FDA found deficiencies at the location, and the cuts will shrink the site's headcount by about 25%. This is one of the three McNeil plants that are covered by a consent decree, as the AP notes.

The FDA has issued an untitled letter to Bristol-Myers Squibb over a sales aid for Ixempra, saying the promotional material is misleading due to unsubstantiated efficacy claims and broadening of the indication. The drug carries a boxed warning for patients with hepatic impairment due to increased risk of toxicity and neutropenia-related death, along with a “Warnings and Precautions” section flagging other risks including peripheral neuropathy.



Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.